A physics-constrained network reconstructed pelvic cone-beam computed tomography from two simulated radiographs with substantially lower error than generative baselines.
Adding early stereotactic body radiotherapy to neoadjuvant chemoimmunotherapy was associated with median progression-free survival of 12.5 versus 6.6 months.
Carbon ion radiotherapy achieved 82.9% two-year locoregional control, while combined immunotherapy was associated with longer overall survival.
Respiratory gating more than halved cranio-caudal motion, while motion-related target-dose deviations largely diminished after accumulation across more than three fractions.
No single patient-specific quality assurance method covered all stereotactic radiotherapy risks, supporting combinations of measurement, independent calculation, imaging, and monitoring.
Regional lymph node irradiation was linked to attenuated local cytokine shifts and nodal damage and cell-death signatures after sinonasal stereotactic radiotherapy.
Adding radiotherapy to systemic treatment was associated with longer overall and progression-free survival without significantly higher acute toxicity.
A nodal-to-primary tumor volume ratio of at least 15% was associated with lower three-year distant metastasis-free survival after extended-field radiotherapy.
Mean treated-breast displacement was 1.6 mm, with larger patient-specific changes near treatment completion and during follow-up.
A 3D-printed jig delivered approximately uniform iridium-192 tumor dose, delayed tumor growth, and caused no observable short-term radiation toxicity in mice.
Hybrid phase-amplitude gating restored dose agreement during regular motion, while irregular breathing increased treatment time and produced inconsistent accuracy.
Off-axis beam optimization preserved target coverage while reducing lung dose and enabling collision-free beam geometry for posterior lung lesions.
Oxygen-ion irradiation showed higher biological effectiveness and more persistent DNA damage than carbon ions or photons in pancreatic cancer cells.
Splitting eight fractions between inhale and exhale breath-holds reduced maximum rib dose from 67.9 to 33.5 Gy without compromising target coverage.
Robust optimization preserved target coverage while reducing lung, heart, esophageal, spinal cord, and estimated immune-cell dose during long-course lung radiotherapy.